bimekizumab
PS0020
Phase 2 small_molecule active
Quick answer
bimekizumab for Moderate to Severe Plaque Psoriasis is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Moderate to Severe Plaque Psoriasis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active